ClinicaliQ Trial Snapshot
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo — Recruiting • Phase III • NCT06804811.
- Ruxolitinib cream safely and effectively treats vitiligo in children aged 6-12 years.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to < 12 years old) with nonsegmental vitiligo. Conditions: NonSegmental Vitiligo Interventions: Ruxolitinib Cream, Vehicle Cream Lead Sponsor: Incyte Corporation Planned Enrollment: 250 participants